<DOC>
	<DOC>NCT02875184</DOC>
	<brief_summary>This is a multicenter, prospective, non-interventional, observational single arm study. Two-hundred patients will be recruited in the Netherlands over a one year period. In all cases, the decision to treat the patient with apremilast will be made prior to the decision to enter the subject into this study. Treatment will be according to routine clinical practice and based on recommendations as per the Summary of Product Characteristics (SPC) of apremilast (Otezla®). Each patient will be followed up for a maximum of 24 months.</brief_summary>
	<brief_title>A Study of Apremilast Use and Effectiveness in Patients With Psoriatic Arthritis in The Netherlands</brief_title>
	<detailed_description>The objective of this non-interventional study is to describe patient reported outcomes, effectiveness and real-life use of apremilast treatment in patients with psoriatic arthritis (PsA).</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Psoriatic</mesh_term>
	<mesh_term>Apremilast</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Inclusion Criter Patients ≥ 18 years of age who understand and voluntarily sign an informed consent form. Patients starting treatment with apremilast for psoriatic arthritis. Refusal to participate in the study. Language barrier for completing the questionnaires. Women who are pregnant or breastfeeding. Hypersensitivity to the active substance or to any of the excipients. Prior exposure to apremilast Initiation of apremilast treatment by a dermatologist for psoriasis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Psoriatic Arthritis</keyword>
	<keyword>Apremilast</keyword>
	<keyword>CC-10004</keyword>
</DOC>